Novel vaccines targeting dendritic cells by coupling allergoids to mannan

被引：34

作者：

Benito-Villalvilla C. ^{[1
]}

Soria I. ^{[2
]}

Subiza J.L. ^{[2
]}

Palomares O. ^{[1
]}

机构：

[1] Department of Biochemistry and Molecular Biology, School of Chemistry, Complutense University of Madrid, Madrid

[2] Inmunotek, S.L., Alcalá de Henares

来源：

Allergo Journal International | 2018年 / 27卷 / 8期

关键词：

Allergen vaccines; Allergen-specific immunotherapy; Allergoids conjugated to mannan; Dendritic cells; Immune tolerance; Regulatory T cells;

D O I：

10.1007/s40629-018-0069-8

中图分类号：

学科分类号：

摘要：

Allergen-specific immunotherapy (AIT) is the single disease-modifying treatment for allergy. Clinical trials show AIT to be safe and effective for many patients; however, it still faces problems related to efficacy, safety, long treatment duration and low patient adherence. There has been intensive research to develop alternative strategies, including novel administration routes, adjuvants or hypoallergenic molecules. Promising results are reported for some of them, but clinical progress is still moderate. Allergoids conjugated to nonoxidized mannan from Saccharomyces cerevisiae have emerged as a novel concept of vaccine targeting dendritic cells (DCs). Preclinical human and animal models demonstrated that allergoids conjugated to mannan enhance allergen uptake, promote healthy responses to allergens by inducing Th1 and T regulatory (Treg) cells, and show clinical efficacy in veterinary medicine. Dose-finding phase II clinical trials in humans are currently ongoing. We review the current stage of allergoids conjugated to mannan as next generation vaccines for AIT. © 2018, The Author(s).

引用

页码：256 / 262

页数：6

共 39 条

[1]

Jutel M., Agache I., Bonini S., Burks A.W., Calderon M., Canonica W., Et al., International Consensus on Allergen Immunotherapy II: mechanisms, standardization, and pharmacoeconomics, J Allergy Clin Immunol, 137, pp. 358-368, (2016)

[2]

Pfaar O., Bonini S., Cardona V., Demoly P., Jakob T., Jutel M., Et al., Perspectives in allergen immunotherapy: 2017 and beyond, Allergy, 73, pp. 5-23, (2018)

[3]

Palomares O., Akdis M., Martin-Fontecha M., Akdis C.A., Mechanisms of immune regulation in allergic diseases: the role of regulatory T and B cells, Immunol Rev, 278, pp. 219-236, (2017)

[4]

Akdis M., Akdis C.A., Mechanisms of allergen-specific immunotherapy: multiple suppressor factors at work in immune tolerance to allergens, J Allergy Clin Immunol, 133, pp. 621-631, (2014)

[5]

Bonertz A., Roberts G.C., Hoefnagel M., Timon M., Slater J.E., Rabin R.L., Et al., Challenges in the implementation of EAACI guidelines on allergen immunotherapy: a global perspective on the regulation of allergen products, Allergy, 73, pp. 64-76, (2018)

[6]

Moingeon P., Adjuvants for allergy vaccines, Hum Vaccin Immunother, 8, pp. 1492-1498, (2012)

[7]

Klimek L., Schmidt-Weber C.B., Kramer M.F., Skinner M.A., Heath M.D., Clinical use of adjuvants in allergen-immunotherapy, Expert Rev Clin Immunol, 13, pp. 599-610, (2017)

[8]

Palomares O., The role of regulatory T cells in IgE-mediated food allergy, J Investig Allergol Clin Immunol, 23, pp. 371-382, (2013)

[9]

Palomares O., Crameri R., Rhyner C., The contribution of biotechnology toward progress in diagnosis, management, and treatment of allergic diseases, Allergy, 69, pp. 1588-1601, (2014)

[10]

Burks A.W., Calderon M.A., Casale T., Cox L., Demoly P., Jutel M., Et al., Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report, J Allergy Clin Immunol, 131, pp. 1288-1296.e3, (2013)

← 1 2 3 4 →